Whitehawk Therapeutics

WHWK

Market cap $153M

MORRISTOWN, N.J., Feb. 26, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced participation at the following investor conferences: TD Cowen 46th Annual Health Care Conference – Dave Lennon, PhD, President and CEO, will participate in a hybrid presentation and fireside chat on Tuesday, March 3 at 10:30 AM ET Leerink 2026 Global Healthcare Conference – executives will participate in investor meetings on Monday, March 9 Citizens Life Sciences Conference – Dave Lennon, PhD, President and CEO, will give a corporate presentation on Tuesday, March 10 at 12:30 PM ET A live webcast of the TD Cowen and Citizens presentations can be accessed by visiting the Whitehawk Therapeutics IR website and will be available for replay for approximately 30 days following the event.

MORRISTOWN, N.J., Feb. 18, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced that Dave Lennon, PhD, President and CEO, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026, at 8:40 AM EST.

Actively recruiting Phase 1 trial for PTK7-targeted antibody-drug conjugate (ADC) HWK-007 IND submitted mid-December 2025 for MUC16-targeted ADC HWK-016, anticipated Phase 1 start this quarter Initial clinical data from both programs anticipated in early 2027 MORRISTOWN, N.J., Jan. 8, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for HWK-007, its PTK7-targeted ADC.

Dr. Dugan brings extensive clinical development leadership to Whitehawk as ADC programs near the clinic MORRISTOWN, N.J. , Dec. 1, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced the appointment of Margaret Dugan, MD, as Chief Medical Officer (CMO).

MORRISTOWN, N.J. , Nov. 26, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced that Dave Lennon, PhD, President and CEO, will participate in a fireside discussion at the Piper Sandler 37th Annual Healthcare Conference in New York City, NY on December 3, 2025, at 12:30 PM ET.

MORRISTOWN, N.J. , Nov. 11, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced that Dave Lennon, PhD, President and CEO, will present at the Jefferies Global Healthcare Conference in London on November 18, 2025, at 11:30 AM GMT.

MORRISTOWN, N.J. , Nov. 6, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced financial results for the third quarter ended September 30, 2025, and provided recent corporate progress.

PTK7 is the third most highly expressed tumor marker among clinically validated and emerging ADC targets, present in ~70% of tumors PTK7 expression is stable across histologic subtype, disease stage and metastatic status in high-potential indications, including lung, ovarian and endometrial cancers Findings support potential of PTK7 as a pan-tumor target, reinforcing Whitehawk's development of PTK7-directed ADC HWK-007 MORRISTOWN, N.J. , Oct. 24, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today presented data from a real-world analysis of Protein Tyrosine Kinase 7 (PTK7) at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a multi-year collaboration with Whitehawk Therapeutics, Inc. (NASDAQ: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugates (ADC) cancer treatments. The collaboration aims to leverage Tempus' proprietary real-world dataset to advance biomarker-.

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 4:50 PM EDT Company Participants David Lennon - President, CEO & Director Conference Call Participants Frank Tang - Morgan Stanley Presentation Frank Tang All right. Good afternoon, everyone.